Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Neurologists’ Likelihood of Prescribing Injectable Parkinson’s disease (PD) Therapies Increases With Education on Patient Attitudes
Movement Disorders
P10 - Poster Session 10 (8:00 AM-9:00 AM)
5-007
OFF episodes occur in majority of PD patients negatively impacting their day-to-day life. Subcutaneous injections of apomorphine have been shown to reduce OFF episodes with a rapid onset of action. Several other products are currently in development for the treatment of motor fluctuations requiring continuous subcutaneous infusion.  We had previously reported that 89% of patients would be willing to self-inject, when there is an associated benefit. We hypothesized the following: 1.  neurologists were unaware of this information (overestimating the impact of “needle phobia”) and as a result may underutilize these effective therapies.  2.  neurologists’ willingness to prescribe injectable therapies would increase after learning this information. 
To evaluate neurologists’ perception of PD patient attitudes towards injectable therapies and determine if education on these attitudes would alter neurologists’ willingness to prescribe these therapies.
Data were collected using an online survey. Our sample (n=200) comprised n=115 Movement Disorder Specialists (MDS) and n=85 General Neurologists. The sample had n=96 physicians who had previously prescribed APOKYN® and n=104 who had not.
54% of general neurologists and 37% of MDS demonstrated a positive change in perceptions about patients’ willingness to use self-injected therapies after reviewing patient survey data (all P<0.05).  This was true amongst 53% of APOKYN® non-users and 35% of APOKYN®  users (all P<0.05).    In addition, 37% of general neurologists and 21% of MDS indicated a greater likelihood of prescribing these treatments (all P< 0.05).
Neurologists may be overestimating the impact of “needle phobia" since there is a discrepancy between PD patients’ willingness to self-inject medications and neurologists’ perceptions.    Educating neurologists about actual patient acceptance of injectable therapies appeared effective, might facilitate more discussions about injectable therapies with patients who have troublesome off time, and may result in greater utilization of these effective therapies.
Authors/Disclosures
Rajeev Kumar, MD, FRCPC (Rocky Mountain Movement Disorders Center)
PRESENTER
The institution of Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Teva Pharmaceuticals. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevel Therapeutics. Dr. Kumar has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Impel Pharma. Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Research Catalyst, LLC. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for CenExel RMCR. Dr. Kumar has stock in Research Catalyst, LLC. Dr. Kumar has stock in CenExel. The institution of Dr. Kumar has received research support from Supernus. The institution of Dr. Kumar has received research support from Sage Therapeutics. The institution of Dr. Kumar has received research support from Prilenia Therapeutics. The institution of Dr. Kumar has received research support from Roche. The institution of Dr. Kumar has received research support from Triplet Therapeutics. The institution of Dr. Kumar has received research support from CHDI Foundation. The institution of Dr. Kumar has received research support from Neurocrine Biosciences. The institution of Dr. Kumar has received research support from Biovie. The institution of Dr. Kumar has received research support from Neuroderm. The institution of Dr. Kumar has received research support from Sanofi. The institution of Dr. Kumar has received research support from Addex Pharma. The institution of Dr. Kumar has received research support from Integrative Research Laboratories. The institution of Dr. Kumar has received research support from Takeda Pharmaceuticals. The institution of Dr. Kumar has received research support from Neuraly. The institution of Dr. Kumar has received research support from Abbvie. The institution of Dr. Kumar has received research support from Cerevel Therapeutics. The institution of Dr. Kumar has received research support from Transposon Therapeutics. The institution of Dr. Kumar has received research support from Lundbeck. The institution of Dr. Kumar has received research support from Biohaven. The institution of Dr. Kumar has received research support from Revance Therapeutics. The institution of Dr. Kumar has received research support from Impax Laboratories. The institution of Dr. Kumar has received research support from Pharma Two B. The institution of Dr. Kumar has received research support from Enterin. The institution of Dr. Kumar has received research support from CND Life Sciences. The institution of Dr. Kumar has received research support from Neuron23. The institution of Dr. Kumar has received research support from Annexon Biosciences. The institution of Dr. Kumar has received research support from Annovis. The institution of Dr. Kumar has received research support from PTC Therapeutics. The institution of Dr. Kumar has received research support from Uniqure. The institution of Dr. Kumar has received research support from Alexza. The institution of Dr. Kumar has received research support from SparkNeuro. The institution of Dr. Kumar has received research support from Praxis. The institution of Dr. Kumar has received research support from Scion Neurostim. The institution of Dr. Kumar has received research support from Cognition Therapeutics. The institution of Dr. Kumar has received research support from Eli Lilly. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Medical Director with CenExel RMCR. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as a Managing Member with Research Catalyst, LLC.
Josh Rossol, PhD (Mindfrog) Dr. Rossol has received personal compensation for serving as an employee of Mindfrog, a Market Research Company serving pharmaceutical clients. Dr. Rossol has received research support from Supernus. Dr. Rossol has received personal compensation in the range of $500,000-$999,999 for serving as a Market Research Vendor with Rigel. Dr. Rossol has received personal compensation in the range of $50,000-$99,999 for serving as a Market Research Vendor with AbbVie. Dr. Rossol has received personal compensation in the range of $500,000-$999,999 for serving as a Market Research Vendor with Supernus. Dr. Rossol has received personal compensation in the range of $50,000-$99,999 for serving as a Market Research Vendor with Santen. Dr. Rossol has received personal compensation in the range of $50,000-$99,999 for serving as a Market Research Vendor with Viatris. Dr. Rossol has received personal compensation in the range of $50,000-$99,999 for serving as a Market Research Vendor with Vistagen.